financetom
Business
financetom
/
Business
/
MongoDB Lifts Full-Year Outlook After Quarterly Beat; Expects Atlas Consumption Slowdown in Fourth Quarter
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MongoDB Lifts Full-Year Outlook After Quarterly Beat; Expects Atlas Consumption Slowdown in Fourth Quarter
Dec 10, 2024 3:56 AM

06:35 AM EST, 12/10/2024 (MT Newswires) -- MongoDB ( MDB ) raised its full-year outlook and reported better-than-expected fiscal third-quarter results, but the database software maker forecast a consumption slowdown for its Atlas cloud platform in the ongoing quarter, sending its shares down early Tuesday.

Adjusted earnings are now set to be in a range of $3.01 to $3.03 per share for fiscal 2025, the company said late Monday, up from its prior guidance of $2.33 to $2.47. Revenue is pegged at $1.97 billion to $1.98 billion, compared with previous projections of $1.92 billion to $1.93 billion. The consensus on FactSet is for non-GAAP EPS of $2.82 and revenue of $1.96 billion.

Consumption growth for MongoDB's ( MDB ) cloud-based developer data platform, Atlas, is anticipated to see a "typical seasonal slowdown" in the fourth quarter, "driven by underlying application usage moderating during the holiday season," Chief Financial Officer Michael Gordon said during an earnings call, according to a Capital IQ transcript. "Since Atlas consumption remained lower on a year-over-year basis in (the third quarter), we expect to see continued deceleration of Atlas year-over-year growth in (the fourth quarter)."

The company's stock gained nearly 2% as of the close of Monday trading but declined 2.9% in premarket activity Tuesday.

MongoDB ( MDB ) expects adjusted EPS to come in between $0.62 and $0.65 for the ongoing quarter on a revenue range of $515 million to $519 million. The Street is currently looking for non-GAAP EPS of $0.63 on revenue of $516.7 million.

"We expect to see a sequential decline in non-Atlas revenue in (the fourth quarter), which is contrary to our normal pattern," Gordon told analysts. "The reason for this is that we experienced a significant additional benefit from multi-year deals in (the third quarter), which we do not expect to recur in (the fourth quarter)."

For the three-month period ended October, the company's adjusted EPS advanced to $1.16 from $0.96 a year ago, exceeding the Street's view for $0.69. Revenue climbed 22% year over year to $529.4 million, topping analysts' $497.2 million estimate.

Subscription revenue jumped 22% to $512.2 million while services inclined 18% to $17.2 million. Atlas grew 26% in the quarter year over year and now represents 68% of total revenue versus 66% in the third quarter of fiscal 2024, Gordon said on the call. The total number of customers grew to more than 52,600 at the end of October from over 50,700 at the end of July.

Gordon will step down from his roles as CFO and chief operating officer of the company at the end of its fiscal year 2025. MongoDB ( MDB ) said it has launched a search process for a new CFO and will evaluate internal and external candidates. Senior Vice President of Finance Serge Tanjga will serve as interim CFO, effective Feb. 1, if the company hasn't named a successor to Gordon by then.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ImmunityBio's Application for Anktiva Approved for Review in UK
ImmunityBio's Application for Anktiva Approved for Review in UK
Feb 13, 2025
03:37 PM EST, 02/13/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Thursday that the UK's Medicines and Healthcare Products Regulatory Agency accepted its marketing authorization application for Anktiva in combination with bacillus Calmette-Guerin to treat certain patients with non-muscle invasive bladder cancer. The application covers patients who do not respond to bacillus Calmette-Guerin and are with carcinoma in situ...
US Transportation Sec'y Duffy requests meeting with Boeing CEO on safety
US Transportation Sec'y Duffy requests meeting with Boeing CEO on safety
Feb 13, 2025
WASHINGTON, Feb 13 (Reuters) - U.S. Transportation Secretary Sean Duffy said on Thursday he has asked the CEO of Boeing ( BA ) to come to Washington, D.C., as soon as possible to discuss quality and safety issues at the company. Following that, I will visit Boeing ( BA ) myself to evaluate firsthand the measures being implemented to ensure...
Walmart's Mexico unit profit edges up, slightly below forecasts
Walmart's Mexico unit profit edges up, slightly below forecasts
Feb 13, 2025
MEXICO CITY, Feb 13 (Reuters) - Walmart's ( WMT ) Mexico and Central America unit reported a 1.4% bump in its fourth-quarter net profit on Thursday, coming in at 15.2 billion Mexican pesos ($729 million), slightly below analysts' forecasts as its general expenses jumped some 15%. Analysts polled by LSEG had forecast profits of some 16.55 billion pesos. Net sales...
Arm Stock Rises As Meta Becomes First Customer For Its New In-House Chip
Arm Stock Rises As Meta Becomes First Customer For Its New In-House Chip
Feb 13, 2025
Arm Holdings ( ARM ) shares are moving higher after the company reportedly announced that Meta has become its first customer for a new in-house chip project. What To Know: According to Financial Times, this marks a major shift in Arm's business model, as it moves from licensing chip designs to producing its own processors, putting it in potential competition...
Copyright 2023-2026 - www.financetom.com All Rights Reserved